Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Maravai Lifesciences Holdings Inc

Healthcare US MRVI

4.99USD
0.15(3.10%)

Last update at 2026-06-04T20:00:00Z

Day Range

4.865.21
LowHigh

52 Week Range

1.6711.50
LowHigh

Fundamentals

  • Previous Close 4.84
  • Market Cap767.22M
  • Volume4447050
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-39.88600M
  • Revenue TTM241.86M
  • Revenue Per Share TTM1.72
  • Gross Profit TTM 90.19M
  • Diluted EPS TTM-1.17

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 551.47M 530.76M 81.70M -5.85300M -16.49800M
Minority interest -270.45800M -287.21300M 66.23M 3.23M 3.61M
Net income 490.66M 469.25M 88.97M -5.20100M -17.73100M
Selling general administrative 129.26M 100.06M 94.25M 48.35M 41.19M
Selling and marketing expenses - - - - -
Gross profit 714.04M 658.68M 204.45M 76.29M 63.07M
Reconciled depreciation 38.10M 24.75M 25.84M 24.08M 22.35M
Ebit 574.22M 554.64M 67.60M 23.99M 17.46M
Ebitda 568.40M 543.67M 93.43M 48.51M 39.81M
Depreciation and amortization -5.82000M -10.97000M 25.84M 24.52M 22.35M
Non operating income net other - 0.28M - - -
Operating income 574.22M 554.64M 67.60M 23.99M 16.44M
Other operating expenses 316.58M 255.84M 183.20M 118.83M 106.46M
Interest expense 20.41M 30.26M 30.74M 29.96M 27.40M
Tax provision 60.81M 61.52M 2.88M -0.65200M 0.42M
Interest income 2.34M - - - -
Net interest income -18.07600M -30.26000M -30.74000M -29.95900M -27.39900M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 60.81M 61.52M 2.88M -0.65200M 0.42M
Total revenue 883.00M 799.24M 284.10M 143.14M 123.83M
Total operating expenses 147.63M 115.28M 103.55M 51.98M 45.69M
Cost of revenue 168.96M 140.56M 79.65M 66.85M 60.77M
Total other income expense net -22.74400M -23.88000M 14.10M -29.84100M -6.47400M
Discontinued operations - - - - -
Net income from continuing ops 490.66M 469.25M 78.82M -5.20100M -16.91500M
Net income applicable to common shares 220.21M 182.04M 76.89M -8.48600M -17.73100M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 1008.24M 1487.45M 2282.32M 1918.28M 1270.69M
Intangible assets 194.96M 220.99M 216.66M 117.57M 177.66M
Earning assets - - - - -
Other current assets 18.14M 17.83M 25.80M 19.70M 11.10M
Total liab 431.04M 697.57M 1377.07M 1372.91M 1115.94M
Total stockholder equity 325.29M 416.75M 545.22M 315.50M 88.51M
Deferred long term liab - - 2.20M 2.70M 3.40M
Other current liab 35.87M 60.53M 89.36M 65.69M 38.55M
Common stock 2.53M 2.51M 2.55M 2.55M 2.58M
Capital stock 2.53M 2.51M 2.55M 2.55M 2.58M
Retained earnings 140.89M 285.74M 404.77M 184.56M 0.85M
Other liab - - 693.38M 713.64M 400.36M
Good will 159.88M 326.03M 283.67M 152.77M 224.28M
Other assets - - 806.13M 812.47M 435.86M
Cash 322.40M 574.96M 632.14M 551.27M 236.18M
Cash and equivalents - - - - -
Total current liabilities 56.97M 87.47M 110.14M 93.78M 130.78M
Current deferred revenue 3.29M 3.36M 3.09M 10.21M 78.06M
Net debt 54.29M 36.01M -46.87600M -16.95900M 354.60M
Short term debt 6.23M 12.85M 11.71M 9.72M 6.00M
Short long term debt 5.44M 5.44M 5.44M 6.00M 6.00M
Short long term debt total 376.69M 610.97M 585.26M 534.31M 590.78M
Other stockholder equity 181.87M 128.50M 137.90M 128.39M 85.12M
Property plant equipment - - 116.59M 46.33M 101.31M
Total current assets 429.15M 699.91M 847.90M 740.04M 331.60M
Long term investments - - - - -
Net tangible assets - - 44.89M 315.50M -313.42000M
Short term investments - - - - -
Net receivables 38.52M 55.72M 146.81M 117.51M 51.02M
Long term debt 290.49M 518.71M 522.00M 524.59M 528.61M
Inventory 50.08M 51.40M 43.15M 51.56M 33.30M
Accounts payable 11.96M 10.73M 5.99M 8.15M 8.17M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - 229.86M -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -0.04400M
Additional paid in capital - - - - -
Common stock total equity - - - 2.55M 2.58M
Preferred stock total equity - - - - -
Retained earnings total equity - - - 184.56M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 7.24M 9.32M 51.69M 53.45M 4.16M
Deferred long term asset charges - - - - -
Non current assets total 579.10M 787.54M 1434.41M 1178.24M 939.09M
Capital lease obligations 80.76M 86.82M 57.83M 3.72M 56.17M
Long term debt total - - - 524.59M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -267.61200M 105.66M 6.07M -17.14800M -3.45100M
Change to liabilities -8.70100M -7.30200M 78.40M 2.55M -1.67000M
Total cashflows from investing activities -267.61200M 105.66M 6.07M -17.14800M -3.45100M
Net borrowings -5.44000M -6.00000M 196.92M -2.64000M 55.43M
Total cash from financing activities -187.49900M -159.04900M 53.21M -4.16700M -9.16700M
Change to operating activities -23.56800M -17.49100M 9.74M 1.52M -12.33600M
Net income 490.66M 469.25M 78.82M -5.20100M -16.91500M
Change in cash 80.87M 315.09M 211.48M 2.83M -12.87300M
Begin period cash flow 551.27M 236.18M 24.70M 21.87M 34.74M
End period cash flow 632.14M 551.27M 236.18M 24.70M 21.87M
Total cash from operating activities 535.98M 368.57M 152.19M 24.11M -0.18600M
Issuance of capital stock 0.00000M 0.00000M 1758.93M - 0.00000M
Depreciation 38.10M 24.75M 25.84M 24.08M 22.35M
Other cashflows from investing activities -12.17300M 120.50M -12.17300M -12.17300M 0.16M
Dividends paid - 153.45M -609.32100M 97.05M 52.06M
Change to inventory 9.46M -21.57400M -19.09900M 0.11M 2.31M
Change to account receivables -22.27200M -70.39100M -33.14400M -1.88800M -4.14600M
Sale purchase of stock 0.00000M 1.71M -1457.98200M - 0.00000M
Other cashflows from financing activities -173.60400M -153.04900M 773.66M -1.52700M 298.09M
Change to netincome 319.96M 45.83M -0.34000M 0.48M -3.71800M
Capital expenditures 17.09M 14.85M 25.41M 17.15M 3.61M
Change receivables - -70.39100M - - -
Cash flows other operating - -68.26000M - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - 315.18M - - -
Change in working capital -45.08200M -176.63100M 35.89M 2.29M -15.84100M
Stock based compensation 18.67M 10.46M 24.63M 1.68M 2.12M
Other non cash items -8.69500M -6.16300M -7.52400M 2.42M 7.79M
Free cash flow 518.89M 353.72M 126.78M 6.97M -3.79700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MRVI
Maravai Lifesciences Holdings Inc		 0.15 3.10% 4.99 - 370.37 3.17 1.01 1.60 1.77
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

Maravai Lifesciences Holdings Inc

10770 Wateridge Circle, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Mr. Carl W. Hull Co-Founder and Exec. Chairman & Interim CEO 1959
Mr. Kevin M. Herde Exec. VP & CFO 1972
Mr. Kurt Oreshack Exec. VP, Gen. Counsel & Sec. 1981
Ms. Christine Dolan Chief Operating Officer of Biologics Safety Testing 1968
Mr. Brian Neel Chief Operating Officer of Nucleic Acid Production 1976
Dr. Peter Michael Leddy Ph.D. Exec. VP & Chief Admin. Officer 1963
Ms. Debra Hart Sr. Director of Investor Relations NA
Ms. Doreen Pippen VP of Marketing NA
Mr. Carl W. Hull Co-Founder & Executive Chairman 1959
Mr. William E. Martin III Chief Executive Officer 1976

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.